Table 6.
Survival Analyses of 122 Patients with Symptomatic Multiple Myeloma
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| OS HR(95% CI) | P-value | OS HR(95% CI) | P-value | |
| Sex=male | 1.448(0.831–2.526) | 0.192 | ||
| Yes | ||||
| No | ||||
| Age | 1.443(0.858–2.425) | 0.166 | ||
| ≧65 years | ||||
| <65 years | ||||
| Severe bone destruction | 1.316(0.764–2.267) | 0.322 | ||
| Yes | ||||
| No | ||||
| Hypercalcemia | 1.273(0.691–2.344) | 0.439 | ||
| Yes | ||||
| No | ||||
| Renal injury | 1.422(0.864–2.341) | 0.166 | ||
| Yes | ||||
| No | ||||
| Serious anemia | 1.326(0.792–2.218) | 0.283 | ||
| Yes | ||||
| No | ||||
| Higher BMPC | 0.824(0.496–1.367) | 0.453 | ||
| Yes | ||||
| No | ||||
| Worse D-S stage | 1.883(0.898–3.951) | 0.094 | ||
| Yes | ||||
| No | ||||
| ALP>187.5IU/L | 7.781(3.156–19.183) | <0.001 | ||
| Yes | ||||
| No | ||||
| Severe hypoalbuminemia | 2.147(1.214–3.797) | 0.009 | ||
| Yes | ||||
| No | ||||
| BNP≧700pg/mL | 1.764(0.990–3.142) | 0.048 | 2.455(1.339–4.501) | 0.004 |
| Yes | ||||
| No | ||||
| Higher LDH | 1.881(1.052–3.363) | 0.033 | ||
| Yes | ||||
| No | ||||
| AL amyloidosis | 1.854(1.074–3.200) | 0.027 | ||
| Yes | ||||
| No | ||||
| Better ITE | 0.126(0.070–0.226) | <0.001 | 0.106(0.058–0.196) | <0.001 |
| Yes | ||||
| No | ||||
| Treatment regimen | 0.484(0.285–0.822) | 0.007 | ||
| With bortezomib | ||||
| Without bortezomib | ||||
Note: The bold font represents statistical significance.
Abbreviations: BMPC, bone marrow plasma cells ratio; D-S staging, Durie Salmon staging; BNP, brain natriuretic peptide; LDH, lactate dehydrogenase; ITE, initial therapeutic effect; OS, overall survival; HR, hazard ratio.